Cipla, a prominent Indian pharmaceutical company, announced that it has entered into a licensing agreement with Novartis Pharma AG (Switzerland) to produce and market the Galvus range, which is used in the treatment of type 2 diabetes, effective from January 1, 2026.
Buy Prime Test Series for all Banking, SSC, Insurance & other exams
According to the regulatory filing, Cipla has signed a perpetual license agreement to manufacture and market Galvus and Galvus combination brands. The drug firm believes that this partnership will enhance its standing in the diabetes category and reinforce its position as one of the major players in the Indian market. The agreement is contingent upon the fulfillment of certain preconditions, as stated by Cipla. The Galvus brand is a prominent name in the Dipeptidyl Peptidase-4 (DPP4) space and a major player in the oral diabetic medication category, according to the drug firm. On the Bombay Stock Exchange (BSE), Cipla’s shares rose by 1.02 percent to close at Rs 901.85 apiece.
You may also read this:
IIT-Bombay and UIDAI join hands to develop touchless biometric system
The Indian Air Force is set to equip the its MiG-29 fighter jets with the…
The Indian Navy has successfully hosted the IONS Maritime Exercise (IMEX) TTX 2026 in Kochi.…
Indonesia has begun to implement the new regulation which is banning children under 16 years…
Sheetal Devi the India's upcoming and rising young star has been named with the prestigious…
The Good news coming from Gujarat in Wildlife conservation as Great Indian Bustard (GIB) chick…
To tighten the risk management in currency markets of India the Reserve Bank of India…